Amcor stock falls after Raymond James reiterates Market Perform rating
Jonathan Young, Chief Operating Officer of Akero Therapeutics, Inc. (NASDAQ:AKRO), recently sold 10,000 shares of the company's common stock. The transaction comes as the stock has shown strong momentum, gaining over 31% in the past six months. According to InvestingPro analysis, the company appears slightly undervalued at current levels. The shares were sold at a weighted-average price of $28.033, with transaction prices ranging from $27.72 to $28.34. Following this transaction, Young holds 218,083 shares directly. The sale was conducted under a pre-established Rule 10b5-1 trading plan, adopted in June 2024. Additionally, Young has indirect holdings of 20,000 shares each in three separate irrevocable trusts, which are managed by his spouse for the benefit of their children. Young disclaims beneficial ownership of these trust-held securities. InvestingPro data shows the company maintains strong liquidity with a current ratio of 17.25, and its stock typically moves independently of broader market trends. Subscribers can access 8 additional ProTips and comprehensive financial metrics for deeper analysis.
In other recent news, Keros Therapeutics announced a voluntary pause in dosing for certain arms of its Phase 2 TROPOS Trial due to unexpected cases of pericardial effusion. However, dosing continues at the 1.5 mg/kg level. The company aims to present topline data from all treatment arms of the trial in the second quarter of 2025.
Meanwhile, Akero Therapeutics has been the subject of positive attention from Citi, which initiated coverage on the company with a Buy rating. This is based on the potential of efruxifermin, a treatment for metabolic dysfunction-associated steatohepatitis (MASH), which is currently being developed by Akero.
Furthermore, Akero reported positive results from its Phase 2b HARMONY study, which evaluated the efficacy of efruxifermin for treating MASH. Over 40% of participants exhibited regression of liver fibrosis after 96 weeks of treatment.
The company has also made significant progress with its Phase 3 SYNCHRONY Outcomes trial for MASH patients with compensated cirrhosis. The first patient has been dosed, marking a critical step for Akero as it now has all three Phase 3 trials of efruxifermin underway.
Finally, investors are eagerly anticipating the Week 96 data release from the ongoing Phase 2b SYMMETRY study, expected in the first quarter of 2025. This data will provide insights into the long-term effects of efruxifermin on MASH patients with fibrosis stage 4.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.